A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies

AIMS: At the time of analysis, two widely used, drug-specific, tumour-cell programmed death ligand 1 (PD-L1) assays were approved by the US Food and Drug Administration for anti-PD-1 therapies: the Dako PD-L1 immunohistochemistry (IHC) 28-8 pharmDx assay and the Dako PD-L1 IHC 22C3 pharmDx assay. Gi...

Descripción completa

Detalles Bibliográficos
Autores principales: Batenchuk, Cory, Albitar, Maher, Zerba, Kim, Sudarsanam, Sucha, Chizhevsky, Vladislav, Jin, Chelsea, Burns, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287558/
https://www.ncbi.nlm.nih.gov/pubmed/30275099
http://dx.doi.org/10.1136/jclinpath-2018-205362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287558/
https://www.ncbi.nlm.nih.gov/pubmed/30275099
http://dx.doi.org/10.1136/jclinpath-2018-205362

Ejemplares similares